VEGFA and peripheral arterial disease: 2015). In relation to aforementioned therapeutic angiogenesis, Isner and coworkers treated rat hearts exposed to ischemia‐reperfusion with recombinant human VEGF protein, and observed beneficial effects in their cardiovascular functions in 1997 (Luo et al. 1997). Since then treatment with recombinant proangiogenic growth factor proteins including VEGF has yielded promising outcomes in various ischemic situations such as peripheral artery diseases, both in experimental settings and in clinical trials (Ko and Bandyk 2014).